Indigo is recognized alongside most ambitious and innovative companies representing breakthrough ideas from all over the world Boston, Massachusetts, May 22, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has been named to the sixth annual CNBC Disruptor 50 List, a ranked list of the most ambitious and innovative companies representing breakthrough ideas from all over the world. Indigo’s #18 ranking caps a remarkable period of company growth, with the early half of 2018 bringing multiple notable milestones—including continuous improvement in Indigo CottonTM yield gains, the development of an on-farm storage program, organic certi

-- Strategic focus on unleashing therapeutic potential of specific orphan GPCRs, including novel family of Mas-Related G-Protein Receptors (Mrgprs) -- Opportunity to pursue novel therapeutics for a broad range of indications; initial focus on neuro-immuno-inflammatory and autoreactive diseases -- Series A investors include The Column Group, 5AM Ventures and Osage University Partners -- Co-founders bring deep expertise in GPCR scientific research and drug development, and proven entrepreneurial track record SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targe

Xconomy San Francisco — Unity Biotechnology has yet to show that its drugs can treat diseases of aging in humans, but it now has $85 million to start those tests. The Brisbane, CA, drug developer priced its initial public offering late Wednesday by selling 5 million shares at $17 apiece, the midpoint of the $16 to $18 range it had previously set. Shares are expected to begin trading Thursday on the Nasdaq exchange under the stock symbol “UBX.” Unity aims to treat diseases of aging at the cellular level. The company is developing drugs that target senescent cells— dormant cells that still secrete proteins that trigger aging or disease in tissue, the company says in its prospectus. By blocking